62 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
RDY Dr. Reddy's Laboratories Ltd $35.7 $5.93B N/A
Article Searches
Cymabay Therapeutics (CBAY) Looks Good: Stock Up 7.2% http://www.zacks.com/stock/news/190670/cymabay-therapeutics-inc-cbay-saw-its-shares-rise-over-7-on-the-day?cid=CS-ZC-FT-190670 Sep 21, 2015 - Cymabay Therapeutics, Inc. (CBAY) was a big mover last session, as the company saw its shares rise over 7% on the day.
AxoGen (AXGN) Looks Good: Stock Adds 13.8% in Session http://www.zacks.com/stock/news/190203/axogen-inc-axgn-saw-its-shares-rise-almost-14-on-the-day?cid=CS-ZC-FT-190203 Sep 16, 2015 - AxoGen, Inc. (AXGN) was a big mover last session, as the company saw its shares rise almost 14% on the day.
AbbVie Seeks FDA Approval for Imbruvica's Label Expansion http://www.zacks.com/stock/news/190147/abbvie-seeks-fda-approval-for-imbruvicas-label-expansion?cid=CS-ZC-FT-190147 Sep 15, 2015 - AbbVie (ABBV) is looking to get Imbruvica approved in the U.S. for the front-line treatment of patients suffering from chronic lymphocytic leukemia.
Sanofi's (SNY) LixiLan Positive in Phase III Diabetes Study http://www.zacks.com/stock/news/189981/sanofis-sny-lixilan-positive-in-phase-iii-diabetes-study?cid=CS-ZC-FT-189981 Sep 14, 2015 - Sanofi (SNY) reported positive top-line data from the second of two pivotal phase III studies (LixiLan-L) on type II diabetes candidate, LixiLan.
AbbVie's Humira Gains FDA Approval for Label Expansion http://www.zacks.com/stock/news/189834/abbvies-humira-gains-fda-approval-for-label-expansion?cid=CS-ZC-FT-189834 Sep 11, 2015 - AbbVie (ABBV) gained ninth FDA approval for Humira for the treatment of patients suffering from moderate-to-severe hidradenitis suppurativa.
Relypsa (RLYP) Looks Good: Stock Rises 8% http://www.zacks.com/stock/news/189717/relypsa-rlyp-adds-8-in-session?cid=CS-ZC-FT-189717 Sep 11, 2015 - Relypsa, Inc. (RLYP) was a big mover last session, as the company saw its shares rise almost 8% on the day.
Impax Hayward Facility Gets FDA Clearance, Shares Rise http://www.zacks.com/stock/news/189499/impax-hayward-facility-gets-fda-clearance-shares-rise?cid=CS-ZC-FT-189499 Sep 09, 2015 - Impax Laboratories (IPXL) received clearance from the FDA for its manufacturing facility at Hayward, CA; shares jumped 12%.
4 Low-Volatility Stocks to Sail Through Market Mayhem http://www.zacks.com/stock/news/189052/4-low-volatility-stocks-to-sail-through-market-mayhem?cid=CS-ZC-FT-189052 Sep 04, 2015 - It has been a topsy-turvy ride for investors so far in 2015.
Allergan Buys Naurex, Boosts Mental Health Portfolio http://www.zacks.com/stock/news/188559/allergan-buys-naurex-boosts-mental-health-portfolio?cid=CS-ZC-FT-188559 Sep 01, 2015 - Allergan (AGN) acquires central nervous system focused company, Naurex, to boost mental disorder portfolio.
AxoGen (AXGN) Shows Strength: Stock Moves 13.2% Higher http://www.zacks.com/stock/news/188100/shares-of-axogen-axgn-rose-over-13-in-the-last-session?cid=CS-ZC-FT-188100 Aug 28, 2015 - AxoGen (AXGN) was a big mover last session, with shares rising over 13% on the day.

Pages: 1234567

<<<Page 6